Objective The aim of the current project is to develop a strong business plan that includes market analysis and clinical validation strategies to commercialise CytaCoat. 1 in 18 patients in a European hospital acquire Healthcare-Associated Infections (HAIs) mainly as a result of colonisation and formation of microbial biofilms on the surface of medical devices that are in lengthy contact with patients. At present, antimicrobial substances and silver agent coating are used as preventative measures, while antibiotics are used for treatment following HAIs. These strategies either contribute to antimicrobial resistance or potentially dangerous due to the release of harmful silver substances in the body. To overcome this, CytaCoat has developed a unique and stable antimicrobial coating that uses non-toxic, biocompatible organic compounds that strongly bind to the surface of the device through covalent bonding. This impedes microbial colonization and reduces the likelihood of antimicrobial resistance to the coating. These features distinguish CytaCoat from all competing products on the market. The first application for the coating are neonatal nasal prongs for non-invasive ventilation support, however the coating can be applied to all invasive and non-invasive medical devices. The research performed to date strongly supports CytaCoat’s ability to hinder microbial colonisation. The coating is easily applied to all devices using a defined protocol developed by the company. This project will help facilitate the road towards commercialisation. Fields of science natural scienceschemical sciencesinorganic chemistrytransition metalsengineering and technologymaterials engineeringcoating and filmsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistancemedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator CYTACOAT AKTIEBOLAG Net EU contribution € 50 000,00 Address RETZIUS VAG 8, HOUSE B3 PLAN 3 17165 SOLNA, STOCKHOLM Sweden See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Östra Sverige Stockholm Stockholms län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
